China Regenerative Medicine International Limited Overview
CRMI is a Hong Kong–domiciled, Cayman-incorporated micro-cap that has migrated from a loss-making regenerative-medicine and tissue-engineering developer — best known for the 2015 approval of the "Aixintong" bioengineered cornea in China — into a small, consumer-facing aesthetic medical and beauty services operator. Today the overwhelming majority of revenue (HK$72.1 M in FY2025; 92% booked in Hong Kong) comes from a clinic platform in Tsim Sha Tsui serving visitors from Mainland China, supplemented by a sub-scale medical services line, licensing income from an independent practitioner, and a nascent health-products trading business in the PRC. The group returned to profitability in FY2024–FY2025, but earnings quality is low: profit has been driven by credit-loss reversals, interest accretion on a large restructured receivable owed by an unnamed PRC service provider, and a one-off tax over-provision release. Liquidity is thin, going-concern uncertainty persists, and the controlling shareholder's financial support underpins the balance sheet.
Company's own description (latest annual results, paraphrased)
In its FY2025 results [AR25], the company describes itself as an investment holding company whose subsidiaries are principally engaged in providing (i) aesthetic medical and beauty products and services and (ii) medical products and services. Its forward-looking statement is generic: it intends to seek opportunities to broaden its scope within healthcare and reallocate resources when appropriate so as to remain a leading pioneer in healthcare products and services.
The 2026 interim report [IR26] adds more operational colour: the group's customers in 2026 are mainly sourced from Mainland China; the group uses the flow of Mainland visitors to Hong Kong to provide them with premium medical aesthetic and value-added health services in Hong Kong; and management acknowledges that cautious consumer sentiment, Hong Kong residents and visitors shifting leisure spending north into the Mainland, and a difficult Chinese economy could constrain customer purchasing power.
Independent characterisation
CRMI is effectively a single-site cross-border aesthetic clinic business with a financing tail. Three features define it:
-
Revenue engine — Hong Kong clinic serving Mainland tourists. Of FY2025 revenue of HK$72.06 M, HK$66.09 M (91.7%) was generated in Hong Kong [AR25]. Management explicitly attributes the FY2024 revenue increase to more PRC visitors attending its Hong Kong clinic centre and the FY2025 decline to fewer such visitors [AR24][AR25]. The business is therefore a play on Mainland outbound medical-aesthetic tourism into Hong Kong, not on the PRC domestic market.
-
Prepaid, over-time service model. Most revenue (HK$61.73 M, 85.7% of FY2025) is recognised over time, consistent with packages/courses of treatment sold in advance and drawn down [AR25]. Contract liabilities (customer prepayments) are therefore a key leading indicator: they were HK$81.09 M at end-2023, HK$11.29 M at end-2024, HK$26.66 M at end-2025 and HK$12.92 M at 30 Jun 2026 [AR24][AR25][IR26].
-
An outsourced/agency operating structure with a PRC service provider. A large portion of cost of sales is "service fees" (HK$22.16 M in FY2025; HK$43.46 M in FY2023) [AR25][AR24]. Historically, an unnamed PRC service provider collected receipts from customers on the group's behalf, was prepaid to cover future operating costs of the aesthetic consulting business, and provided services on the group's behalf. The resulting receivable (≈HK$236.2 M) was restructured in March 2024 into an interest-free, five-instalment repayment plan running to December 2028 [AR24]. This receivable dwarfs equity and is the single most important balance-sheet item.
Revenue model mix [AR24][AR25]
| Revenue stream | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Aesthetic medical and beauty services (HK$ '000) | 57,834 | 82,004 | 56,099 |
| Medical services (HK$ '000) | 8,308 | 5,263 | 8,015 |
| Trading of health products (HK$ '000) | 0 | 0 | 6,255 |
| Others — licensing income from independent practitioner (HK$ '000) | 3,345 | 3,350 | 1,686 |
| Total revenue (HK$ '000) | 69,487 | 90,617 | 72,055 |
| Revenue by timing of recognition | FY2023 | FY2024 | FY2025 |
| Recognised at a point in time (HK$ '000) | 7,399 | 23,050 | 10,323 |
| Recognised over time (HK$ '000) | 62,088 | 67,567 | 61,732 |
Characterisation: ~78% service (aesthetic), ~11% medical service, ~9% product trading, ~2% licensing (FY2025). There is no subscription or IP-licensing revenue in the pharmaceutical sense; the "licensing" line is income for providing administrative support, supplies and access to space/facilities to an independent medical practitioner who delivers aesthetic services [AR25].
Value-chain position, customers and end-markets
Value-chain position: Downstream, consumer-facing service delivery (clinic operation and treatment packages). CRMI does not manufacture aesthetic devices, injectables or skincare; materials costs were only HK$7.98 M in FY2025 [AR25].
Customer types: Individual retail consumers, predominantly Mainland Chinese visitors to Hong Kong; no customer exceeded 10% of revenue in FY2024 or FY2025 [AR24][AR25].
End-markets: (1) Non-surgical medical aesthetics and beauty treatments in Hong Kong; (2) health management/medical services; (3) health-products distribution in the PRC (new in FY2025).
- Historical aggregator descriptions [YF] list services such as health assessment, detox and immune enhancement programmes, non-surgical aesthetic services, basic skincare, skin rejuvenation, hair revitalising, line firming, partial remodelling and intimate rejuvenation. These are not itemised in the latest filings reviewed and should be treated as indicative.
Strategy
Stated strategy (themes, paraphrased from [AR25][IR26])
-
Broaden scope within healthcare and reallocate resources to remain among leading healthcare products and services providers (boilerplate repeated in FY2024, FY2025 and H1 2026 filings).
-
Cross-border tourism model: use Mainland visitor flows to Hong Kong to sell premium medical aesthetic and value-added health services.
-
Adaptation to a weak Chinese consumer: management states it may need to adjust business strategies and seek new opportunities given constrained purchasing power and willingness to consume.
-
Cost control: stricter control of service fees (FY2024–FY2025) and administrative expense reductions (FY2025 admin −HK$8.08 M).
-
Receivable recovery: liquidity strategy explicitly depends on timely repayment of the restructured receivable [AR25].
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status | Source |
|---|---|---|---|---|
| Health-products trading launch | FY2025 | New revenue line (HK$6.26 M); prepayments to suppliers HK$10.48 M | Ongoing | [AR25] |
| Premises lease renewal/expansion | FY2025 | HK$26.0 M additions to HK non-current assets; ROU assets up to HK$20.9 M | Completed | [AR25] |
| Staffing and marketing build-out | H1 2026 | Headcount 24 → 33 (YoY); advertising up to HK$1.63 M from HK$0.44 M | Ongoing | [IR26] |
| New Share Option Scheme | 27 Jun 2025 | 10% mandate (30.4 M shares); no grants | Adopted | [IR26] |
| Governance upgrades | 2,025 | New INED, NED; D&O insurance from Dec 2025 | Completed | [AR25][BRD25] |
| Equity financing (stated intent) | FY2024 going-concern plan | Group "actively seeking" equity financing | No issuance through 30 Jun 2026 | [AR24][IR26] |
| Changzhou Bomei 33.3% investment (RMB10.25 M) | Dec 2023 – 2025 | Plan to sell health products (own and third-party brands) in Shanghai and Jiangsu | Under negotiation as of Mar 2025; FY2025 results state no concrete material investment plans — treated as stalled/not completed | [DT23][AR24][AR25] |
| New articles of association | 26 Jun 2026 | Adopted at AGM | Completed | [ETN] |
Sustainability/ESG commitments and cost programmes
No quantified ESG commitments or formal cost-programme targets are disclosed. The annual report notes it is printed on environmentally friendly paper (FY2024 AR cover) — the only explicit environmental reference identified.
Medium-term targets / guidance
None. The company provides no revenue, margin or earnings guidance and has no investor-day materials.
Products & Services
Filings disclose service categories, not named product SKUs or prices. The catalogue below is organised by segment; items not itemised in primary filings are labelled accordingly.
Aesthetic Medical and Beauty Services segment
| Offering | Description | Target customer | Launch / status | Pricing model | Source |
|---|---|---|---|---|---|
| Hong Kong clinic centre — medical aesthetic treatments | Non-surgical medical aesthetic services delivered at the group's Hong Kong clinic; specific modalities (injectables, energy devices, etc.) not itemised | Mainland Chinese visitors; some local HK residents | Operating since the 2020–21 pivot; core revenue driver | Predominantly prepaid packages recognised over time (85.7% of FY2025 revenue over time) | [AR25][IR26] |
| Beauty and skincare services | Basic skincare, youthful-skin solutions, hair revitalising, line firming, partial remodelling, intimate rejuvenation (aggregator list) | Same | Not dated in filings | — | [YF] |
| Value-added health services | Premium value-added health services bundled for Mainland visitors | High-spending Mainland visitors | Referenced in 2026 interim MD&A | — | [IR26] |
| Licensing to independent practitioner ("Others") | Provision of administrative support, office supplies and access to space/facilities to an independent medical practitioner who provides aesthetic services | One independent practitioner | Ongoing FY2023–FY2025 | Licensing fee (HK$1.69 M FY2025; HK$3.35 M FY2024) | [AR25] |
| Trading of health products | Sale of health products, apparently in the PRC (PRC revenue rose to HK$5.96 M in FY2025); prepayments to suppliers of HK$10.48 M at end-2025 | PRC distributors/consumers (not specified) | New in FY2025 (HK$6.26 M) | Product sale, point-in-time recognition | [AR25] |
Medical Services segment
| Offering | Description | Target customer | Status | Pricing model | Source |
|---|---|---|---|---|---|
| Medical services / health management | Provision of medical products and services; aggregator profiles mention health assessment, detox, "inner-body balance", organ nourishment and immune enhancement programmes | Individual clients | Revenue HK$8.02 M FY2025; persistently loss-making | — | [AR25][YF] |
Legacy regenerative-medicine assets (historical; current status not disclosed)
| Legacy asset | Description | Status |
|---|---|---|
| Aixintong (艾欣瞳) bioengineered cornea | Acellular porcine corneal stroma product; approved April 2015 by China's drug regulator; promoted as the world's first bioengineered corneal product [MOO] | No revenue or carrying value identifiable in FY2023–FY2025 filings; status not publicly disclosed |
| Oxford cell and stem-cell therapy technology centre (2014) | Collaboration with the University of Oxford | Not referenced in recent filings; status not publicly disclosed |
| China Stem Cell Clinical Application Center (HK Science Park, design began Q2 2015) | Planned clinical stem-cell facility | Not referenced in recent filings |
| Five adult tissue cell banks (Q3 2015) | Cell banking near PRC production facilities and in Hong Kong | Not referenced in recent filings |
| Regenerative medicine cell therapy centres (Suzhou, Tianjin — planned) | Announced expansion plans | Not referenced in recent filings |
Analytical note: The company retains the "Regenerative Medicine" name and a biotechnology industry classification on several data platforms, but the current disclosed business has no visible regenerative-medicine product revenue, no R&D expense line and no intangible assets. The name is a legacy artefact.
Financial Narrative
Notes: FY2023–FY2025 figures are from the company's audited results [AR24][AR25]. FY2021 is on a gross revenue basis; FY2022 onward appears to be net (see 4.7).
Company-reported operating lines [AR24][AR25]: notes and sources
Note: FY2025 "Other income and other loss" of HK$17.99 M is dominated by HK$17.96 M of interest accretion on the restructured receivable (a non-cash unwinding of discount) [AR25]. FY2024 operating profit embedded HK$17.58 M of accretion, a HK$17.28 M modification loss and a HK$12.29 M ECL reversal [AR24].
Margins and growth (%)
Revenue CAGR: FY2021–FY2025 4-year CAGR = −29.0% (distorted by the gross-to-net presentation change); FY2022–FY2025 3-year CAGR = +20.2% (like-for-like net basis). Analyst calculations.
Commentary. The P&L tells three different stories depending on the lens. On a headline basis, CRMI has posted two consecutive profitable years and EPS rose 55% in FY2025 to HK 9.05 cents [AR25]. On an operating basis, however, the business shrank in FY2025: revenue fell 20.5% and gross profit fell 27.3% because fewer Mainland visitors came to the Hong Kong clinic, and S&P's standardised operating income turned slightly negative [AR25][SPG]. The FY2025 net profit increase came from (i) the absence of the FY2024 HK$17.28 M modification loss, (ii) a HK$12.34 M tax credit arising from over-provision in prior years, and (iii) an HK$8.08 M cut in administrative expenses [AR25]. Excluding the tax credit and the HK$17.96 M accretion, FY2025 core pre-tax profit was approximately negative HK$1.6 M (15.19 − 17.96 + 1.15 ECL), i.e., roughly breakeven. FY2024's gross margin step-up to 63.6% from 28.0% was driven by tighter control of service fees paid to the outsourced provider [AR24] — a genuine improvement, but one dependent on renegotiated third-party economics.
Balance sheet
Sources: FY2021–FY2022 [SPG]; FY2023–FY2025 [AR24][AR25] (S&P values agree with filings where overlapping, except S&P "other receivables" classification).
Interim balance sheet (30 Jun 2026) [IR26]: total assets HK$143.24 M; cash HK$1.82 M; other receivables (net) HK$96.68 M; shareholders' loans HK$21.23 M (current 3.63; non-current 17.60); lease liabilities HK$17.02 M; contract liabilities HK$12.92 M; net current assets HK$34.20 M; equity HK$56.76 M.
Commentary. The balance sheet is dominated by the restructured PRC receivable. At end-2025, gross other receivables were HK$149.86 M against an ECL allowance of HK$38.00 M, leaving HK$111.86 M net — more than twice group equity of HK$53.47 M [AR25]. The service provider repaid ≈HK$51.03 M during FY2025 [AR25], which is the only reason the group could cut shareholder loans from HK$49.10 M to HK$30.11 M. All debt is owed to shareholders (mainly the chairman's camp) or to landlords (leases); there are no bank borrowings. Equity has been rebuilt from HK$11.79 M (end-2023) to HK$56.76 M (Jun 2026), but accumulated losses still stand at ≈HK$2.79 billion against share premium of ≈HK$3.22 billion — a measure of how much capital the listed vehicle has consumed since 2001 [IR26].
Cash flow [SPG; consistent with filings where checked]
H1 2026 cash flow [IR26]: operating cash outflow HK$3.94 M (H1 2025: outflow HK$15.47 M); financing outflow HK$1.06 M; FX effect −HK$1.34 M; cash fell from HK$8.17 M to HK$1.82 M.
Commentary. FY2024's strong HK$18.3 M operating cash flow coincided with the start of receivable repayments. FY2025 OCF collapsed to HK$4.1 M despite HK$51 M of receivable repayments — implying that much of the repayment was absorbed by working capital (supplier prepayments of HK$10.48 M, rising trade receivables) and lease/loan repayments, with some proceeds possibly classified outside operating activities. H1 2026 shows the most concerning pattern: revenue up 52% yet operating cash outflow, because revenue growth largely reflected drawing down prepaid packages (contract liabilities fell HK$13.7 M in six months) rather than fresh cash sales [IR26].
Ratios (analyst calculations unless stated)
ROIC method: NOPAT = reported operating profit × (1 − 16.5%); invested capital = equity + total debt − cash at year end. FY2024: 15.77 / (25.20 + 53.69 − 22.70) = 28.1% on year-end, 34.4% on average capital; FY2025: 13.69 / (53.47 + 51.31 − 8.17) ≈ 14.2% year-end, ≈18.4% average. These returns are inflated by non-cash accretion income; on an underlying basis returns are near zero. [SPG] reports TTM ROE 64.2% and ROIC 97.3% — the latter is distorted by its overstated cash figure.
Cash conversion: The traditional CCC is of limited relevance; the economically meaningful working-capital item is contract liabilities (customer prepayments), which historically funded the business (negative CCC) and are now unwinding.
H1 2026 vs H1 2025 [IR26]
Key observation: no interest accretion on the receivable was recognised in H1 2026 (vs HK$8.10 M in H1 2025) [IR26]; the filing does not explain why. Underlying operating profit therefore improved significantly (from roughly −HK$0.1 M ex-accretion/ECL in H1 2025 to ≈HK$4.4 M in H1 2026), which is the first genuine operating inflection in the recent record.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Products/services |
|---|---|---|
Aesthetic medical and beauty services | Provision of medical beauty products and services; also houses the "others" licensing income and (from FY2025) trading of health products | Non-surgical aesthetic treatments, beauty services, treatment packages; space/administrative licensing to an independent practitioner; health-products trading (PRC) |
Medical services | Provision of medical products and services | Health management / medical services (not itemised in filings) |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Aesthetic medical and beauty services revenue (HKD Mn) | 61.18 | 85.35 | 64.04 |
Medical services revenue (HKD Mn) | 8.31 | 5.26 | 8.02 |
Total revenue (HKD Mn) | 69.49 | 90.62 | 72.06 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment result | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Aesthetic segment profit/(loss) as reported (HKD Mn) | -87.73 | 41.15 | 37.38 |
Medical segment profit/(loss) as reported (HKD Mn) | -2.63 | -3.47 | -2.17 |
Total segment profit/(loss) (HKD Mn) | -90.37 | 37.68 | 35.21 |
Results by Segment — Reported aesthetic segment result
| Item (HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Reported aesthetic segment result (HKD Mn) | -87.73 | 41.15 | 37.38 |
Less interest accretion on other receivables (HKD Mn) | 0 | -17.58 | -17.96 |
Add back loss on modification of receivables (HKD Mn) | 0 | 17.28 | 0 |
Add back ECL provision / less ECL reversal (HKD Mn) | 83.00 | -12.29 | 1.15 |
Underlying aesthetic segment operating result (HKD Mn) | -4.73 | 28.56 | 20.57 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Aesthetic reported segment margin (%) | -143.4 | 48.2 | 58.4 |
Aesthetic underlying segment margin (%) | -7.7 | 33.5 | 32.1 |
Medical segment margin (%) | -31.7 | -66.0 | -27.1 |
Aesthetic revenue YoY growth (%) | 0 | 39.5 | -25.0 |
Medical revenue YoY growth (%) | 0 | -36.7 | 52.3 |
Aesthetic share of total revenue (%) | 88.0 | 94.2 | 88.9 |
Medical share of total revenue (%) | 12.0 | 5.8 | 11.1 |
Revenue by Segment (Half-Yearly)
| Segment (six months, HKD Mn) | H1 2025 | H1 2026 | YoY (%) |
|---|---|---|---|
Aesthetic revenue | 24.16 | 37.14 | 53.7 |
Medical revenue | 3.23 | 4.59 | 42.1 |
Aesthetic segment profit | 13.56 | 19.58 | 44.4 |
Medical segment loss | -1.10 | -1.44 | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 282.90 | 41.54 | 69.49 | 90.62 | 72.06 |
Gross profit (HKD Mn) | 67.73 | 37.62 | 19.42 | 57.65 | 41.92 |
Operating income, S&P standardised (HKD Mn) | 61.63 | 11.81 | -26.11 | 6.14 | -0.44 |
Pre-tax income (HKD Mn; FY21–22 derived from S&P pretax margin) | 64.30 | 8.27 | -107.70 | 17.75 | 15.19 |
Net income attributable (HKD Mn) | 51.83 | 4.56 | -107.70 | 17.75 | 27.53 |
EPS basic (HK cents; FY21–22 S&P rounded, consolidation-adjusted) | 18 | 2 | -37.60 | 5.83 | 9.05 |
EPS diluted (HK cents) | 18 | 2 | -37.60 | 5.83 | 9.05 |
Dividends per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Revenue (HKD K) | 69,487 | 90,617 | 72,055 |
Cost of sales (HKD K) | -50,064 | -32,963 | -30,139 |
Gross profit (HKD K) | 19,423 | 57,654 | 41,916 |
Other income and other loss (HKD K) | 2,393 | 458 | 17,985 |
Selling and distribution expenses (HKD K) | -6,644 | -6,626 | -5,540 |
Administrative and other expenses (HKD K) | -38,891 | -44,892 | -36,815 |
ECL (provision)/reversal on other receivables (HKD K) | -83,001 | 12,290 | -1,154 |
Operating profit/(loss), as reported (HKD K) | -106,720 | 18,884 | 16,392 |
Finance costs (HKD K) | -979 | -1,132 | -1,203 |
Profit/(loss) before tax (HKD K) | -107,699 | 17,752 | 15,189 |
Income tax (expense)/credit (HKD K) | 0 | 0 | 12,336 |
Profit/(loss) for the year (HKD K) | -107,699 | 17,752 | 27,525 |
Depreciation — PP&E (HKD K) | 574 | 664 | 662 |
Depreciation — right-of-use assets (HKD K) | 10,743 | 10,295 | 9,195 |
EBITDA, reported op. profit + D&A (HKD K, analyst calc.) | -95,403 | 29,843 | 26,249 |
Employee benefit expense incl. directors (HKD K) | 15,990 | 16,577 | 12,744 |
Service fees in cost of sales (HKD K) | 43,462 | 23,054 | 22,159 |
Material costs (HKD K) | 6,602 | 9,909 | 7,980 |
Advertising and marketing (HKD K) | 1,364 | 1,041 | 1,108 |
Auditor's remuneration (HKD K) | 850 | 840 | 1,000 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin (%) | 23.94 | 90.58 | 27.95 | 63.62 | 58.17 |
Operating margin, S&P standardised (%) | 21.79 | 28.42 | -37.58 | 6.77 | -0.61 |
Pre-tax margin (%) | 22.73 | 19.90 | -154.99 | 19.59 | 21.08 |
Net margin (%) | 18.32 | 10.97 | -154.99 | 19.59 | 38.20 |
Revenue YoY growth (%) | 55.32 | -85.32 | 67.29 | 30.41 | -20.48 |
Margin (company-reported basis)
| Margin (company-reported basis) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Reported operating margin (%) | -153.6 | 20.8 | 22.7 |
EBITDA margin, analyst calc. (%) | -137.3 | 32.9 | 36.4 |
EBITDA margin excl. receivable accretion/ECL/modification (%) | -17.9 | 19.7 | 13.1 |
Liquidity & Coverage Ratios
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash and equivalents (HKD Mn) | 9.93 | 1.85 | 3.33 | 22.70 | 8.17 |
Total debt incl. leases and shareholder loans (HKD Mn) | 35.82 | 72.01 | 50.19 | 53.69 | 51.31 |
Net debt (HKD Mn) | 25.89 | 70.16 | 46.86 | 30.99 | 43.14 |
Total current assets (HKD Mn) | 258.39 | 249.09 | 168.58 | 58.31 | 86.04 |
Total current liabilities (HKD Mn) | 147.31 | 158.17 | 147.79 | 58.87 | 75.23 |
Working capital (HKD Mn) | 111.08 | 90.92 | 20.79 | -0.56 | 10.81 |
Other receivables, S&P classification (HKD Mn) | 196.91 | 237.71 | 156.43 | 28.02 | 52.98 |
Balance Sheet
| Balance sheet detail (HKD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (HKD Mn) | 185.90 | 135.71 | 168.06 |
Total equity (HKD Mn) | 11.79 | 25.20 | 53.47 |
Total liabilities (HKD Mn) | 174.10 | 110.51 | 114.59 |
Short-term debt: current shareholders' loans + current leases (HKD Mn) | 24.02 | 8.22 | 12.09 |
Long-term debt: non-current shareholders' loans + leases (HKD Mn) | 26.17 | 45.47 | 39.21 |
Shareholders' loans total (HKD Mn) | 35.21 | 49.10 | 30.11 |
Lease liabilities total (HKD Mn) | 14.98 | 4.59 | 21.20 |
Bank borrowings (HKD Mn) | 0 | 0 | 0 |
Goodwill and intangibles (HKD Mn) | 0 | 0 | 0 |
Net other receivables (current + non-current, HKD Mn) | 156.43 | 98.43 | 111.86 |
Contract liabilities (HKD Mn) | 81.09 | 11.29 | 26.66 |
Current tax liabilities (HKD Mn) | 25.29 | 24.87 | 13.17 |
Right-of-use assets (HKD Mn) | 14.45 | 4.15 | 20.90 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | -3.02 | -12.43 | 10.79 | 18.30 | 4.09 |
Capital expenditure (HKD Mn) | 0.81 | 2.59 | 0.27 | 0.63 | 0.07 |
Free cash flow (HKD Mn) | -3.83 | -15.03 | 10.52 | 17.68 | 4.02 |
Dividends paid (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Current ratio (x) | 1.75 | 1.57 | 1.14 | 0.99 | 1.14 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE, on average equity (%) | n.m. (negative equity base movement) | 96.0 | 70.0 |
ROA, on average assets (%) | -57.9 (year-end assets) | 11.0 | 18.1 |
ROIC, NOPAT/(equity + debt − cash), approx. (%) | — | 34.4 | 18.4 |
Debt / equity (x) | 4.26 | 2.13 | 0.96 |
Shareholders' loans / equity — company "gearing ratio" (x) | 2.99 | 1.95 | 0.56 |
Net debt / EBITDA (x) | — | 1.04 | 1.64 |
Interest coverage, reported op. profit / finance costs (x) | — | 16.7 | 13.6 |
Asset turnover (x) | 0.37 | 0.56 | 0.47 |
Days sales outstanding (days) | 6.3 | 2.5 | 25.8 |
Days inventory outstanding (days) | 3.2 | 2.6 | 24.6 |
Days payables outstanding (days) | 18.0 | 42.5 | 36.4 |
Cash conversion cycle (days) | -8.5 | -37.4 | 14.0 |
Business Lines
| Line | H1 2025 | H1 2026 | YoY (%) |
|---|---|---|---|
Revenue | 27,391 | 41,734 | 52.4 |
Cost of sales | -9,509 | -17,418 | 83.2 |
Gross profit | 17,882 | 24,316 | 36.0 |
Gross margin (%) | 65.3 | 58.3 | -7.0 pts |
Other income, gain and loss | 8,338 | 235 | -97.2 |
Selling and distribution | -2,361 | -2,752 | 16.6 |
Administrative and other | -15,233 | -17,372 | 14.0 |
Finance costs | -657 | -1,063 | 61.8 |
ECL reversal/(provision) | -3,360 | 1,259 | — |
Profit before tax / for the period | 4,609 | 4,623 | 0.3 |
Basic EPS (HK cents) | 1.51 | 1.51 | 0.0 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong revenue (HKD Mn) | 68.33 | 89.93 | 66.09 |
PRC revenue (HKD Mn) | 1.16 | 0.69 | 5.96 |
Total (HKD Mn) | 69.49 | 90.62 | 72.06 |
Growth / mix (%)
| Growth / mix (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong YoY growth (%) | 0 | 31.6 | -26.5 |
PRC YoY growth (%) | 0 | -40.7 | 766.4 |
Hong Kong share of revenue (%) | 98.3 | 99.2 | 91.7 |
PRC share of revenue (%) | 1.7 | 0.8 | 8.3 |
Revenue by Region (Half-Yearly)
| Region (six months, HKD Mn) | H1 2025 | H1 2026 |
|---|---|---|
Hong Kong revenue (HKD Mn) | 27.09 | 38.51 |
PRC revenue (HKD Mn) | 0.30 | 3.23 |
Region Assets & Liabilities
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Hong Kong non-current assets (HKD Mn) | 17.28 | 6.96 | 23.13 |
PRC non-current assets (HKD Mn) | 0.04 | 0.03 | 0.02 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | HK$0.31 (8 Oct 2026, 09:36 HKT) | [SPG] |
52-week change | −57.86% | [SPG] |
50-day / 200-day moving average | HK$0.23 / HK$0.33 | [SPG] |
Since-IPO performance | ≈ −96.7% (as of Feb 2026) | stoxray |
Average daily volume (20-day) | ≈61,900 shares (≈HK$15–20k/day) | [SPG] |
Beta (5Y) | −0.69 (statistically unreliable for illiquid stock) | [SPG] |
Last corporate action | 10-to-1 reverse split, 6 Sep 2023 | [SPG] |
Reference price points (HKD) | Date | Source |
| 0.40 | 20 Feb 2026 | stoxray |
| 0.345 | 30 Apr 2026 | [MOO] |
| 0.227 | ~Jul 2026 | [ETN] |
| 0.270 | 22 Jul 2026 | [ETN] |
| 0.232 | 4 Aug 2026 | [SPG] |
| 0.295 | 29 Sep 2026 | [SPG] |
| 0.31 | 8 Oct 2026 | [SPG] |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | HK$94.3 M | 304.25 M shares |
Net debt (30 Jun 2026) | HK$36.4 M | Shareholder loans 21.23 + leases 17.02 − cash 1.82 [IR26] |
Enterprise value | HK$130.8 M | Market cap + net debt |
TTM revenue | HK$86.4 M | 72.06 − 27.39 + 41.73 |
TTM net profit | HK$27.5 M | 27.53 − 4.61 + 4.62 |
P/E (TTM, reported) | 3.4x | — |
P/E (TTM, excl. HK$12.3 M tax credit) | 6.2x | — |
EV/Sales (TTM) | 1.51x | — |
EV/EBITDA (TTM, reported op. profit + D&A ≈HK$27.0 M) | 4.8x | — |
EV/EBITDA (TTM, excl. ≈HK$9.9 M accretion) | 7.6x | — |
P/B (30 Jun 2026 equity HK$56.76 M) | 1.66x | — |
P/TBV | 1.66x | No intangibles |
Peer Comparison
| Company | P/E | EV/Sales | Dividend | Source |
|---|---|---|---|---|
CRMI | 3.4x reported / 6.2x adj. | 1.51x | — | Analyst calc. |
EC Healthcare | Negative (loss-making) | ≈0.21–0.26x (consensus-based) | Yield ≈1.5% (2025) | marketscreener |
Perfect Medical | — | — | 100%+ payout | [PM26] |
Capital Markets
| Item | Status |
|---|---|
Analyst coverage / consensus | None — no analyst estimates available [SWS] |
Dividend history | No dividends paid or proposed FY2023–FY2025 or H1 2026 [AR25][IR26] |
Dividend policy | No stated payout policy |
Buyback authorisation | General repurchase mandate renewed at 26 Jun 2026 AGM (standard 10%); no repurchases executed [ETN][IR26] |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile (30 Jun 2026) | Shareholders' loans: HK$3.63 M current, HK$17.60 M non-current; leases: HK$8.68 M current, HK$8.34 M non-current; no bank debt [IR26] |
Analyst Conclusions
Management guidance
No quantitative guidance. Qualitatively, management expects the Chinese economy to remain challenging in 2026, warns that customer purchasing power may be constrained, and says it may adjust strategy and seek new opportunities while continuing to target Mainland visitors [IR26].
Consensus growth expectations
None available (no sell-side coverage).
Bull case
-
Genuine operating inflection in H1 2026. Revenue rose 52.4% and profit before tax held at HK$4.6 M despite zero accretion income (vs HK$8.1 M a year earlier), implying underlying operating profit improved by roughly HK$4–5 M [IR26]. If sustained, FY2026 could be the first year of clean, operations-driven profit.
-
Receivable monetisation could transform the balance sheet. Net other receivables of HK$96.7 M at Jun 2026 exceed the entire market cap; continued instalments on the 2024 schedule (to Dec 2028) would retire shareholder loans and fund growth [AR24][IR26].
-
Cheap on any normalised measure. At ≈6x adjusted P/E and 1.7x book, with tax losses sheltering Hong Kong profits [IR26], modest earnings stability could rerate an illiquid stock sharply (it rose 35% in a month in mid-2025 [SWS]).
Bear case
-
Liquidity is perilous. Cash of HK$1.82 M against HK$60.4 M current liabilities, negative H1 operating cash flow and a going-concern material uncertainty mean the company depends on the receivable counterparty and the controlling shareholder [IR26][AR25].
-
Earnings are largely accounting-driven. In FY2025, accretion (HK$18.0 M) plus a tax over-provision release (HK$12.3 M) exceeded reported net profit of HK$27.5 M; revenue fell 20.5% [AR25]. H1 2026 growth was partly funded by drawing down prepaid packages (contract liabilities −HK$13.7 M) rather than new cash [IR26].
-
Opaque counterparty and governance history. The PRC service provider is unnamed; the receivable required an HK$83.0 M impairment in FY2023 and a scope-limited audit; a 19% shareholder is bankrupt with part of the stake pledged to a state AMC; chair and CEO roles are combined [AR24][IR26].
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Receivable instalment receipts | Ongoing; next annual disclosure Mar 2027 | Whether repayments continue on schedule; ECL movements |
| FY2026 annual results | Late Mar 2027 | Revenue trajectory, underlying margin, audit opinion, going-concern language |
| Controlling shareholder support | Undertaking runs to 30 Jun 2027 | Renewal/extension; further shareholder loans |
| Equity raising | Any time under general mandate | Pricing, dilution, identity of subscribers |
| Contract liabilities | Each reporting date | Rebuild indicates healthy new package sales; further decline signals demand weakness |
| Mainland visitor trends to Hong Kong | Monthly | Leading indicator for clinic revenue |
| Health-products trading | FY2026 results | Scale, margin, related-party features |
| All Favour block (19.15%) | Unpredictable | Trustee or pledgee disposal — overhang or change-of-control trigger |
| Bomei investment | Unclear | Formal termination or completion |
Analyst verdict
China Regenerative Medicine International is no longer a regenerative-medicine company in any operational sense. It is a micro-cap Hong Kong aesthetic clinic business, generating roughly HK$70–90 M of annual revenue from Mainland visitors, wrapped around a large, opaque receivable owed by an unnamed PRC service provider. Its name, biotech classification and legacy cornea story are historical artefacts; investors should evaluate it as a cross-border consumer-services stub with significant balance-sheet risk.
The good news is real but narrow. Gross margins have structurally improved since service-fee renegotiation, the audit opinion became unmodified for FY2025, receivable repayments of roughly HK$51 M arrived in FY2025, and H1 2026 delivered the first clean operating improvement in years — revenue up 52% and stable profit without accretion income. If the counterparty keeps paying and Mainland traffic holds, the remaining receivable alone is worth more than the current HK$94 M market capitalisation.
The bad news is more fundamental. Reported profits over FY2024–FY2025 owe more to credit-loss reversals, discount unwinding and a tax over-provision release than to clinic economics; cash fell to HK$1.82 M at mid-2026 with negative operating cash flow; the auditor still flags material going-concern uncertainty; and the group's survival depends on two parties outside minority shareholders' control — the PRC counterparty and the controlling shareholder, who is simultaneously chairman, CEO, largest owner and main lender. Peer data (Perfect Medical −14.7% revenue, EC Healthcare −8.9% with a HK$413 M loss) show the Hong Kong aesthetics sector is contracting, not recovering.
Verdict: Speculative / high risk — suitable only as a special-situation position sized for total loss. The investment case hinges almost entirely on receivable collection, not operating growth. The stock screens cheap, but the discount reflects credible solvency, governance and dilution risk. Evidence of two further on-schedule receivable instalments, rebuilt contract liabilities and positive operating cash flow would be required before treating the earnings base as investable.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed / tenure | Background (as disclosed or reported) | Shareholding |
|---|---|---|---|---|
Mr. Wang Chuang (王闖) | Chairman, CEO, Executive Director, Compliance Officer, Authorised Representative | Executive chairman since Oct 2019 (aggregator date 18 Oct 2019); CEO since 9 Jul 2020 — ~7 years | — | 73,875,530 shares (24.28%) [IR26] |
Ms. Luo Min (雒敏) | Non-executive Director | 25 Apr 2025 | — | Nil disclosed |
Mr. Leung Man Fai (梁文輝) | INED; Chair, Audit Committee | At least since 2023 | — | 31,000 shares (0.01%) |
Ms. Huo Chunyu (霍春玉) | INED | At least since Oct 2020 | — | Nil disclosed |
Mr. Zhou Xudong (周旭東) | INED; Chair, Nomination and Remuneration Committees | 30 Jun 2025 | INED roles at other listed companies incl. Jiangsu Huayang Intelligent; vice-president role at "Zhonglou" referenced in appointment notice | Nil disclosed |
Directors' Remuneration
| Person | Year | Total compensation |
|---|---|---|
Wang Chuang (Chairman & CEO) | FY2024 | ≈HK$1.2 M total |
Key management excl. directors | H1 2026 | HK$485k (salaries 476k + pension 9k) |
Key management excl. directors | H1 2025 | HK$711k |
Group employee remuneration incl. directors | FY2025 | HK$12.74 M |
Board & Management Changes
| Date | Change | Source |
|---|---|---|
2 Jul 2024 | Khoo Wun Fat (Qiu Huanfa) resigns as company secretary; Wong Po Tin (Huang Baotian) appointed | [MOO] |
By Aug 2024 | Board reduced to 4 (Wang; INEDs Huo, Liu Ming, Leung); prior NED Tsang Ho Yin no longer listed | Director list 20 Aug 2024 |
25 Apr 2025 | Luo Min appointed NED; Wong Po Tin resigns | [IR25] |
30 Jun 2025 | Zhou Xudong appointed INED and chairs Nomination/Remuneration; Dr. Liu Ming resigns; Chan Lok Tung appointed company secretary/authorised representative | [BRD25] |
Major Shareholders
| Holder | Shares | % of issued | Notes |
|---|---|---|---|
Wang Chuang | 73,875,530 | 24.28 | Chairman/CEO; beneficial owner |
All Favour Holdings Ltd | 58,254,776 | 19.15 | Owned 40% Nat-Ace Wood Industry (Li Ren), 20% Honour Top and 40% directly by Dai Yumin; Mr. Dai bankrupt since 31 Mar 2022, estate vested in trustees; 15,774,466 shares pledged to Optimus Prime Management |
Trustees of Dai Yumin's estate (Arab Osman Mohammed; Wong Kwok Keung) | 58,342,276 (deemed) | 19.18 | Deemed interest via All Favour plus options (lapsed by end-2025) |
Li Ren | 60,392,776 (deemed incl. 2,138,000 direct) | 19.85 | Via Nat-Ace / All Favour plus direct holding |
Changzhou Yaoguang Enterprise Management Consulting LLP (Lei Changjuan, GP) | 26,240,000 | 8.62 | Held via Yao Guang (Hong Kong) Enterprise Ltd |
Changzhou Minxing Enterprise Management Consulting Services LLP (Kong Yudong, GP) | 16,060,000 | 5.28 | Held via Zhong Min Starry (Hong Kong) Ltd |
Central Huijin Investment Ltd (via China Orient Asset Management → Optimus) | 15,774,466 (security interest) | 5.18 | Pledge over part of All Favour's stake |
Leung Man Fai (INED) | 31,000 | 0.01 | — |
Competitive Landscape
Key Competitors
| Competitor | Ticker / status | Segment overlap | Latest revenue | Relative positioning |
|---|---|---|---|---|
Perfect Medical Health Management | 1830.HK | Hong Kong medical aesthetics and health management | HK$962.3 M (FY to Mar 2026), −14.7% [PM26] | Scale leader in HK; debt-free; 100%+ dividend payout; closing underperforming outlets |
EC Healthcare (醫思健康) | 2138.HK | Medical, aesthetic medical, beauty and wellness in HK/Macau/PRC | HK$3,770.2 M (FY to Mar 2026), −8.9% [EC26] | Largest diversified private healthcare platform in HK; loss-making; cited loss of cross-border consumption |
Modern Beauty Salon Holdings | 0919.HK | HK beauty and aesthetic services | — | Long-established beauty-services chain |
Miricor Enterprise Holdings | 1827.HK | HK aesthetic medical services | — | Smaller listed HK aesthetic clinic operator |
Beauty Farm Medical and Health Industry | 2373.HK | PRC beauty and aesthetic medical chains | — | PRC-based; competes for the same Mainland consumer domestically |
So-Young International | SY (Nasdaq) | PRC aesthetic platform and clinics | — | Channels Mainland demand to domestic clinics |
Mainland domestic medical-aesthetic clinic chains (e.g., in Shenzhen/Guangzhou) | Various, private | Same consumer, lower price | — | Structural substitute; Mainland clinics increasingly competitive on price |
Independent HK private clinics (Tsim Sha Tsui / Causeway Bay) | Private | Direct local competition | — | Fragmented, intense |
Upstream product owners with clinic channels (e.g., Imeik, Bloomage, Huadong Medicine aesthetics) | A-share / HK listed | Indirect (products, brand control) | — | Control pricing of key injectables/consumables |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | CRMI (FY Dec 2025) | Perfect Medical (FY Mar 2026) | EC Healthcare (FY Mar 2026) |
|---|---|---|---|
Revenue (HKD Mn) | 72.1 | 962.3 | 3,770.2 |
Revenue growth (%) | -20.5 | -14.7 | -8.9 |
Net profit (HKD Mn) | 27.5 | 178.3 | -412.9 |
Net margin (%) | 38.2 (21.1 pre-tax) | 18.5 | -11.0 |
R&D intensity (%) | — | Not disclosed / n.m. | Not disclosed / n.m. |
Dividend policy | — | ≥100% payout, 11th year | — |
“—” = not publicly disclosed.



